Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
| ▸ | SREBF2 | Q12772 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16091748 | 0.87 | NOS2 (0.37) | TLR8KDM4EALDH1A1TSHRNOS2 | |
| SCHEMBL15629833 | 0.87 | HTT (0.35) | ALDH1A1NOS2HPGDHSD17B10POLB | |
| SCHEMBL16091759 | 0.84 | ESR1 (0.34) | TLR8KDM4EALDH1A1TSHRHPGD | |
| SCHEMBL16572668 | 0.77 | ALDH1A1 (0.36) | KDM4EALDH1A1TSHRNOS2HPGD | |
| SCHEMBL15629834 | 0.73 | GAA (0.37) | KDM4EALDH1A1NOS2HPGDHSD17B10 | |
| SCHEMBL6884393 | 0.73 | CYP3A4 (0.35) | ALDH1A1 | |
| SCHEMBL16091776 | 0.70 | TLR8 (0.34) | TLR8KDM4EALDH1A1TSHRNOS2 | |
| SCHEMBL16091765 | 0.69 | KDM4E (0.37) | TLR8KDM4EALDH1A1TSHRNOS2 | |
| SCHEMBL26065401 | 0.69 | KCNA3 (0.39) | KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL16091753 | 0.68 | TERT (0.33) | KDM4EALDH1A1NOS2SKP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9371303-B2 | Diphenylmethane derivatives as SGLT2 inhibitors | GREEN CROSS CORPORATION (KR) | 2016-06-21 | — | — | US | disclosed |
| US-9340521-B2 | Method for dual inhibition of SGLT1 and SGLT2 using diphenylmethane derivatives | GREEN CROSS CORPORATION (KR) | 2016-05-17 | — | — | US | disclosed |
| US-20150152075-A1 | NOVEL DIPHENYLMETHANE DERIVATIVES AS SGLT2 INHIBITORS | GREEN CROSS CORPORATION (KR) | 2015-06-04 | — | — | US | disclosed |
| US-20140274918-A1 | METHOD FOR DUAL INHIBITION OF SGLT1 AND SGLT2 USING DIPHENYLMETHANE DERIVATIVES | GREEN CROSS CORPORATION (KR) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152075-A1 | NOVEL DIPHENYLMETHANE DERIVATIVES AS SGLT2 INHIBITORS | SLC5A2, SLC5A1, SLC2A8 | TLR8 1145/4885KDM4E 1804/4885ALDH1A1 1076/4885 |
| US-20140274918-A1 | METHOD FOR DUAL INHIBITION OF SGLT1 AND SGLT2 USING DIPHENYLMETHANE DERIVATIVES | SLC5A2, SLC5A1, SLC10A2 | TLR8 2460/4885KDM4E 767/4885ALDH1A1 691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.